Knowde Enhanced TDS
Identification & Functionality
- Food Ingredients Functions
- Pharma & Nutraceuticals Functions
- Ingredients
- Curcumin, Fennel
Features & Benefits
- Benefit Claims (Health)
- Food Ingredients Features
Applications & Uses
- Applications
- Dosage Form
Technical Details & Test Data
- Clinical Data
Rifencin and Gi Disease:
- RIFENCIN is a natural remedy whose active principals act on the symptoms of gastro-intestinal disorders like Irritable Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS). The combination of curcumin and fennel offers a combination of complementary active principals.
- Curcumin is known in traditional medicine for its capacity to increase bile production, to help relieve the symptoms of indigestion: feeling of "full stomach", flatulence, slow digestion.
- Fennel is also traditionally known for the symptomatic treatment of: mild gastrointestinal spastic disorders, flatulence, bloating.
Rifencin Is Delivered With a Complete Package of Information, Including Bioxtract Proprietary:
- Pre-clinical acute oral toxicity trial in rats showing no particular effect and classifying the product in the danger 5 category DL50 superior 5,000 mg/kg.
- Phase I clinical trial demonstrating bioavailability of RIFENCIN's active principles.
- Phase II randomized, double-blind, multicentre, placebo-controlled clinical trial evaluating the efficacy of RIFENCIN in 120 patients suffering from functional gastrointestinal symptoms on a period of 30 days.
- Observational clinical study, prospective, non-randomized, real-life of RIFENCIN on 253 patients suffering from Intestinal Bowel Syndrome (IBS).
- Phase Ll Randomised, Double-blind, Multicentre, Placebo Controlled Clinical Trial Evaluating the Eficacy of Rifencin
- In 120 patients suffering from functional gastrointestinal symptoms on a period of 30 days.
- RIFENCIN was significantly superior to placebo in reducing functional gastrointestinal symptoms.
- A significantly higher number of patients in the RIFENCIN group had symptom remission, compared to the placebo group.
- Symptoms improvement in significantly higher in RIFENCIN group at each assesement Day (day 10, 20, 30).
- RIFENCIN improves all aspects of Quality of Life in patients with functional gastrointestinal disorders.
- RIFENCIN has an excellent safety profile.
- Technical Data
- Significantly greater decrease in IBS Symptoms Severity Score (IBS-SSS).
- Significantly greater decrease in abdominal pain (visual analog scale pain) 64% less pain compared to placebo
- Significant improvement in quality of life
- Observational Clinical Study. Prospective, Not-randomized Rea-life of Rifencin on 253 Patients Suffering From Intestinal Bowel Syndrome (IBS)
- Significant decrease in IBS Symptoms Severity Score (1BS-SSS) (p>0.0001) 45% of the severity score
- Significant decrease of IBS specific symptoms (p> 0.0001)
- Significant improvement (339%) of the score of quality of life (lBS-QoL) (p0.0001)
